Clinical trial
Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma
NCT00412919 · Bayside Health, Other · Terminated
Key facts
| NCT number | NCT00412919 |
|---|---|
| Title | Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma |
| Official title | A Prospective, Single-Arm, 2-Stage, Open-label, Phase II Trial of Azacitidine in Relapsed and Refractory Multiple Myeloma. |
| Lead sponsor | Bayside Health, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Azacitidine |
| Enrollment | 7 |
| Start date | Dec 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Dec 19, 2006 |
| Last update posted | Dec 16, 2013 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: